One possibility is that such tumours contain a concurrent mutation in another oncogene that activates the same signalling pathway as KRAS. For this reason, we examined our tumours for BRAF mutations, which are found in 1–2% of NSCLC (Naoki et al, 2002). This evidence concerns the gene KRAS and non-small cell lung carcinoma.